STAB earnings
Statera Biopharma Inc. (STAB) earnings releases and earnings dates - real-time wire coverage of every quarterly report.
Recent earnings items
- Statera Biopharma, Inc. Files Form 12b-25FORT COLLINS, Colo., March 31, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the Company has filed a Form 12b-25 with the U.S. Securities and Exchange Commission to extend until April 15, 2022 the due date for filing the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021. Statera Biopharma has been unable to complete its financial statements for the full year 2021 due to a delay experienced in completing its financial statements and other disclosures in t
- Statera Biopharma, Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on March 31, 2022Live Conference Call and Webcast at 5:30 p.m. ET FORT COLLINS, Colo., March 28, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today that the Company will host a conference call and live audio webcast on Thursday, March 31, 2022, at 5:30 p.m. ET, to discuss its corporate and financial results for the fourth quarter and full year ended December 31, 2021. Conference Call & Webcast Details DateThursday, March 31, 2022Time5:30 p.m. ETLive Audio Webcasthttps://edge.media-server.com/mmc/p/yffrdzzpTeleph
- Statera Biopharma Provides Third Quarter 2021 Financial and Corporate UpdateFORT COLLINS, Co., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today reported important corporate events and financial results for the third quarter ended September 30, 2021. Statera Biopharma was formerly known as Cleveland BioLabs, Inc. and merged with Cytocom Inc. on July 27, 2021. "We are pleased with our operational progress to integrate the portfolio and advance our clinical programs as we prepare to initiate several clinical trials during 2022, including a pivotal Phase 3 trial for our lead drug candidate, STAT-201, in pediatri
- Statera Biopharma, Inc. to Report Third Quarter 2021 Financial ResultsFORT COLLINS, Colo., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today that the Company will host a conference call and live audio webcast on Monday, November 15, 2021, at 5:30 p.m. ET, to discuss its corporate and financial results for the third quarter of 2021. Conference Call & Audio Webcast Details Date Monday, November 15, 2021Time 5:30 p.m. ET Telephone Access: U.S. and Canada 800-937-6813Telephone Access: International 213-660-0853Access Code for All Callers 2973387Live Audio Webcast https://edge.media-server.com/mmc/